- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Multiple myeloma
- Meeting Date: August 2019
- Public Summary Document (PSD) August 2019 PBAC Meeting - (PDF 706KB)
- Public Summary Document (PSD) August 2019 PBAC Meeting - (Word 181KB)
Lenalidomide – August 2019
LENALIDOMIDE, 5 mg, 10 mg, 15 mg, 25 mg, Capsule, Revlimid®, Celgene Pty Ltd.
Last updated
31 January 2020